The US FDA’s Office of Hematology and Oncology Products is encouraging policy makers and drug developers to focus on cross labeling as an alternative to independent development of still more PD-1/PD-L1 checkpoint inhibitors for oncology.
During a National Cancer Policy Forum workshop focusing on “Advancing Progress in the Development of Combination Cancer Therapies with...